Results 151 to 160 of about 26,572 (220)

Risk of Cardiac Disease in a Population-Based Cohort of Myotonic Dystrophy Type 1 and Type 2 in the United States. [PDF]

Neurol Genet
Johnson NE, Bhandaru V, Andrews JG, Jaff T, Venkatesh YS, Raucci FJ, Soim A, Ciafaloni E, Rice MM, as the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).   +11 more
europepmc   +1 more source

Myotonic dystrophy

, 2019
Yuranga Weerakkody, Arlene Campos, Daniel Bell   +2 more
openaire   +1 more source

Pre- and postsynaptic upregulation of FasII synergistically underlies neuropathological and behavioral phenotypes in a Drosophila model of myotonic dystrophy. [PDF]

Nat Commun
Koon AC, Yeung KYW, Wu Y, Leong LI, Cheung JTP, Chen ZS, Peng SI, Armstrong NS, Frank CA, Magneron P, Gomes-Pereira M, Fung JMS, Bargiela A, Moreno N, Poyatos-Garcia J, Vilchez J, Huguet-Lachon A, Brewer CK, Zinter M, Beck ES, Artero R, Gourdon G, Budnik V, Thomson T, McCabe BD, Chan HYE.   +25 more
europepmc   +1 more source

Co-Opting MBNL-Dependent Alternative Splicing Cassette Exons to Control Gene Therapy in Myotonic Dystrophy. [PDF]

Ann Neurol
Carrell ST, Carrell EM, Giovenco R, Davidson BL.   +3 more
europepmc   +1 more source

Elevated Levels of Active GSK3β in the Blood of Patients with Myotonic Dystrophy Type 1 Correlate with Muscle Weakness. [PDF]

Int J Mol Sci
Jennings K, Tian C, Brown RL, Horn PS, Schoser B, Kushlaf H, Timchenko NA, Timchenko L.   +7 more
europepmc   +1 more source

Genetic anticipation and cardiac conduction abnormalities in myotonic dystrophy type 1: implications for early stratification from a multicenter registry. [PDF]

Int J Cardiol Heart Vasc
Lorca R, Alen A, Moliner-Abós C, de Frutos F, Báez-Ferrer N, Peña-Peña ML, Villacorta E, Ripoll-Vera T, Zorio E, Martínez-Gimeno A, Bermúdez-Jiménez J, Limeres J, Tiron C, Larrañaga-Moreira JM, Cabrera-Romero E, García-Pavía P, Espinosa MA, Piqueras J, García-Hernández S, Palomino-Doza J, Soriano-Amores M, Moris G, Carrillo-Mora LM, Syris P, Alvarez-Velasco R, Gimeno JR, Muñoz C.   +26 more
europepmc   +1 more source

circARHGAP10 as a candidate biomarker and therapeutic target in myotonic dystrophy type 1. [PDF]

Mol Ther Nucleic Acids
Baci D, Tastsoglou S, Provenzano C, Perfetti A, Izzo M, Lisanti M, Frolova S, Voellenkle C, Tascini AS, Cardani R, Cardinali B, Meola G, Falcone G, Martelli F.   +13 more
europepmc   +1 more source

Cardiac Involvement in Myotonic Dystrophy Type 1: Mechanisms, Clinical Perspectives, and Emerging Therapeutic Strategies. [PDF]

Int J Mol Sci
Ginjupalli VKM, Reisqs JB, Cupelli M, Chahine M, Boutjdir M.   +4 more
europepmc   +1 more source

Differential pathology and susceptibility to MBNL loss across muscles in myotonic dystrophy mouse models. [PDF]

JCI Insight
Davenport ML, Fong A, Montoya-Vazquez G, de Moura MFA, Bubenik JL, Swanson MS.   +5 more
europepmc   +1 more source